Fig. 1: Suitability for autologous haematopoietic stem cell transplantation as a treatment for multiple sclerosis. | Nature Reviews Neurology

Fig. 1: Suitability for autologous haematopoietic stem cell transplantation as a treatment for multiple sclerosis.

From: Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT

Fig. 1

Neurological (top) and haematological (bottom) variables on the left are associated with a positive recommendation (green profile) for autologous haematopoietic stem cell transplantation (AHSCT). The numbers (age, disease duration, Expanded Disability Status Scale (EDSS) score) are indicative to illustrate the principles but are not intended as cut-off values. The profile on the far left therefore represents the ideal candidate for AHSCT. Variables on the right are adverse factors and, when they are prevalent, AHSCT is not recommended (red profile). Specific considerations for relapsing–remitting multiple sclerosis (MS) and progressive MS are shown in the central boxes with traffic light indicators of suitability for AHSCT. DMT, disease-modifying therapy; HE-DMT, high-efficacy DMT; ME-DMT, medium-efficacy DMT. aAHSCT could be considered in older, biologically fit people on an individual basis. bWithin a clinical trial or study.

Back to article page